SCHEMBL25269656

SCHEMBL25269656

Cn1cc(-c2ccncc2)c(-c2ccc(F)cc2F)n1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 3/20 0.69
CSNK1E P49674 3/20 0.69
MAPK13 O15264 2/20 0.69
MAPK12 P53778 2/20 0.69
MAPK11 Q15759 2/20 0.69
MAPK14 Q16539 2/20 0.69
PDE4A P27815 2/20 0.50
PDE4B Q07343 2/20 0.50
PDE10A Q9Y233 2/20 0.50
PDE3B Q13370 1/20 0.50
PDE3A Q14432 1/20 0.50
BRAF P15056 13/20 0.49
MAP4K4 O95819 1/20 0.48
EGFR P00533 1/20 0.48
FRK P42685 1/20 0.48
MAPK9 P45984 1/20 0.48
CSNK1A1 P48729 1/20 0.48
MAPK3 P27361 3/20 0.46
MAPK1 P28482 3/20 0.46
KCNH2 Q12809 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25218871 0.87 CSNK1D (0.68) CSNK1DCSNK1EMAPK13MAPK12MAPK11
SCHEMBL15022099 0.86 CSNK1D (0.58) CSNK1DCSNK1EMAPK13MAPK12MAPK11
SCHEMBL3272515 0.86 BRAF (0.61) CSNK1DCSNK1EMAPK13MAPK12MAPK11
SCHEMBL25263176 0.84 MAPK13 (0.66) CSNK1DCSNK1EMAPK13MAPK12MAPK11
SCHEMBL5259262 0.83 CSNK1D (0.69) CSNK1DCSNK1EMAPK13MAPK12MAPK11
SCHEMBL15022104 0.83 MAPK13 (0.54) CSNK1DCSNK1EMAPK13MAPK12MAPK11
SCHEMBL5698604 0.82 CSNK1D (1.00) CSNK1DCSNK1EMAPK13MAPK12MAPK11
SCHEMBL5257540 0.82 CSNK1D (1.00) CSNK1DCSNK1EMAPK13MAPK12MAPK11
SCHEMBL25220251 0.81 CSNK1D (0.75) CSNK1DCSNK1EMAPK13MAPK12MAPK11
SCHEMBL15022103 0.80 MAPK13 (0.51) CSNK1DCSNK1EMAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192699-A1 COMPOUNDS AS CASEIN KINASE INHIBITORS Gritscience Biopharmaceuticals Co., Ltd. (CN) 2023-06-22 US disclosed
US-20230192699-A1 COMPOUNDS AS CASEIN KINASE INHIBITORS Gritscience Biopharmaceuticals Co., Ltd. (CN) 2023-06-22 US disclosed
US-20230192699-A1 COMPOUNDS AS CASEIN KINASE INHIBITORS Gritscience Biopharmaceuticals Co., Ltd. (CN) 2023-06-22 US disclosed
EP-4126878-A1 COMPOUNDS AS CASEIN KINASE INHIBITORS Gritscience Biopharmaceuticals Co., Ltd. (CN) 2023-02-08 EP disclosed
CN-115298183-A Compounds as casein kinase inhibitors 北京原基华毅生物科技有限公司 2022-11-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192699-A1 COMPOUNDS AS CASEIN KINASE INHIBITORS CSNK2A3, CSNK1A1, CSNK1G3 CSNK1D 10/4885CSNK1E 9/4885MAPK13 54/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.